Nagoya Firm Goodman To Commence Drug-Eluting Stent Trials In Japan And Europe
This article was originally published in PharmAsia News
Nagoya-headquartered medical device maker Goodman plans to start a clinical study for its drug-eluting stent in Japan and Europe in 2012
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.